CARLSBAD, Calif., Dec. 7, 2016 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense
therapeutics, today announced that management will present a
company overview at the BMO Capital Markets Prescriptions for
Success Healthcare Conference on Wednesday,
December 14 in New York,
NY.
A live webcast of the presentation will be available on the
"Investors & Media" section of the Ionis website. The
replay will be available within 48 hours and will be archived for a
limited time.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases.
Using its proprietary antisense technology, Ionis has created a
large pipeline of first-in-class or best-in-class drugs, with over
a dozen drugs in mid- to late-stage development. Drugs
currently in Phase 3 development include volanesorsen, a drug Ionis
is developing and plans to commercialize through its wholly owned
subsidiary, Akcea Therapeutics, to treat patients with either
familial chylomicronemia syndrome or familial partial
lipodystrophy; IONIS-TTRRx, a drug Ionis is developing
with GSK to treat patients with TTR amyloidosis; and
SPINRAZA™ (nusinersen), a drug Ionis is developing
with Biogen to treat infants and children with spinal muscular
atrophy. Ionis' patents provide strong and extensive
protection for its drugs and technology. Additional
information about Ionis is available at www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Ionis
Pharmaceuticals' business and the therapeutic and commercial
potential of Ionis' technologies and products in development,
including SPINRAZA, IONIS-TTRRx and volanesorsen.
Any statement describing Ionis' goals, expectations, financial or
other projections, intentions or beliefs is a forward-looking
statement and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a
business around such drugs. Ionis' forward-looking statements
also involve assumptions that, if they never materialize or prove
correct, could cause its results to differ materially from those
expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Ionis. As a result, you
are cautioned not to rely on these forward-looking
statements. These and other risks concerning Ionis' programs
are described in additional detail in Ionis' annual report on Form
10-K for the year ended December 31,
2015, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis
Pharmaceuticals, Inc. SPINRAZA™ is a trademark of Biogen.
Logo - http://photos.prnewswire.com/prnh/20151221/317736LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-the-bmo-capital-markets-prescriptions-for-success-healthcare-conference-300374131.html
SOURCE Ionis Pharmaceuticals, Inc.